Kaempferol attenuated cisplatin-induced cardiac injury via inhibiting STING/NF-κB-mediated inflammation

Area of Science:

• Cardiology
• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cardiovascular complications are a significant adverse effect of conventional cancer chemotherapy, particularly cisplatin.
• Cisplatin-induced cardiotoxicity hinders effective cancer treatment.
• Kaempferol (KPF) is known for its cardioprotective and anti-inflammatory properties.

Purpose of the Study:

• To investigate the protective effects of kaempferol (KPF) against cisplatin-induced heart injury.
• To elucidate the molecular mechanisms underlying KPF's cardioprotective action.

Main Methods:

• In vivo studies to assess KPF's effect on cisplatin-induced cardiac dysfunction and injury.
• In vitro experiments using H9c2 cells to evaluate KPF's impact on apoptosis and inflammation.
• Molecular analysis focusing on the STING/NF-κB pathway.

Main Results:

• Kaempferol (KPF) demonstrated significant protection against cardiac dysfunction and injury induced by cisplatin in vivo.
• KPF markedly reduced cisplatin-induced apoptosis and inflammatory responses in H9c2 cells.
• The protective effects were associated with the modulation of the STING/NF-κB signaling pathway.

Conclusions:

• Kaempferol (KPF) exhibits substantial potential in mitigating cisplatin-induced cardiac injury.
• Modulation of the STING/NF-κB pathway is a key mechanism for KPF's cardioprotective effects.
• Natural compounds containing KPF with anti-inflammatory properties warrant further investigation for treating chemotherapy-induced cardiotoxicity.